VRTX
Vertex Pharmaceuticals Incorporated
NASDAQ · USHealthcareBiotechnology
$480.50-1.06%
Price as of Jul 20, 2026
VRTX profitability
Vertex Pharmaceuticals Incorporated profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 86.3%
- EBITDA margin
- 44.0%
- EBIT margin
- 39.0%
- Net margin
- 35.4%
- Free cash flow margin
- 30.3%
Returns
- Return on equity
- 22.4%
- Return on assets
- 16.4%
- Return on invested capital
- 22.4%
- Asset turnover
- 0.47x
Cash efficiency
- Cash from operations
- $4.2B
- Cash per share
- $29
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.